

1 **Early Improvement of Acute Respiratory Distress Syndrome in Patients with COVID-19:**  
2 **Insights from the Data of ICU Patients in Chongqing, China**

3 Zhu Zhan<sup>1,2</sup>, Xin Yang<sup>3</sup>, Hu Du<sup>1</sup>, Chuanlai Zhang<sup>1</sup>, Yuyan Song<sup>4</sup>, Xiaoyun Ran<sup>1</sup>, An Zhang<sup>1\*</sup>,  
4 Mei Yang<sup>5\*</sup>

5 <sup>1</sup>Department of Intensive Care Unit, The Second Affiliated Hospital of Chongqing Medical  
6 University, Chongqing, China.

7 <sup>2</sup>Chongqing Key Laboratory of Ultrasound Molecular Imaging, The Second Affiliated Hospital  
8 of Chongqing Medical University, Chongqing, China.

9 <sup>3</sup>Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of  
10 Chongqing Medical University, Chongqing, China.

11 <sup>4</sup>Department of Intensive Care Unit, Chongqing public health medical center, Chongqing, China.

12 <sup>5</sup>Department of Intensive Care Unit, Chongqing Sixth People's Hospital, Chongqing, China.

13 **\*Correspondence:**

14 Dr. An Zhang, Department of Intensive Care Unit, The Second Affiliated Hospital of Chongqing  
15 Medical University, Chongqing, China. 76 Linjiang Rd, Yuzhong District, Chongqing 400010,  
16 China. Email: [zhangan@hospital.cqmu.edu.cn](mailto:zhangan@hospital.cqmu.edu.cn).

17 Dr. Mei Yang, Department of Intensive Care Unit, Chongqing Sixth People's Hospital,  
18 Chongqing, China. 301 Nancheng Avenue, Nan'an District, Chongqing 400060, China. Email:  
19 [418092179@qq.com](mailto:418092179@qq.com).

20

## 21 **Abstract**

22 Acute respiratory distress syndrome (ARDS) may be the main cause of death in patients with  
23 coronavirus disease 2019 (COVID-19). Herein, we retrospect clinical features, outcomes and  
24 ARDS characteristics of 75 intensive care unit (ICU) patients with COVID-19 in Chongqing,  
25 China. We found a 5.3% case fatality rate of the ICU patients in Chongqing. 93% patients  
26 developed ARDS during the intensive care, and more than half were moderate. However, most  
27 of the patients (55%) supported with high flow nasal cannula (HFNC) oxygen therapy, but not  
28 mechanical ventilation. Nearly one third of patients with ARDS got an early improvement  
29 (eiARDS), and the rate is much higher than the other causes of ARDS in a previous study.  
30 Patients with eiARDS had a higher survival rate and lower length of ICU stay. The age (< 55  
31 years) is an independent predictor for the eiARDS, and stratification of COVID-19 patients by  
32 age is recommended.

33 **Keywords:** COVID-19; acute respiratory distress syndrome; Chongqing; critically ill

## 34 **Introduction**

35 On December 2019, Wuhan (Hubei province, China) reported a cluster cases of unknow cause of  
36 pneumonia, which were later identified as coronavirus disease 2019 (COVID-19)(1). This  
37 contagious disease was caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-  
38 2), and was declared to be a worldwide pandemic by World Health Organization (WHO) on  
39 March 11, 2020(2). As of 23 May 2020, a total of more than 5 000 000 cases and 330 000 deaths  
40 had been reported worldwide(3).

41 The leading cause of COVID-19 death may be the severe respiratory failure caused by acute  
42 respiratory distress syndrome (ARDS)(4). Because according to some autopsy results, the lesions

43 are primarily in the lungs, characterized by diffuse alveolar damage. Other organs, such as the  
44 heart tissue, have no obvious histological changes(5–7). Previous studies reported that about  
45 48.6% of patients with COVID-19 had ARDS, among which 29% patients had died, and the  
46 mortality rate increased with the severity of ARDS(8,9). Therefore, it is needed to fully  
47 understand the features of ARDS in patients with COVID-19.

48 In this study, we described epidemiology, clinical features, laboratory findings, treatments, and  
49 outcomes of intensive care unit (ICU) patients with COVID-19 in Chongqing, China, the  
50 adjoining areas of Hubei province. And we identified a subphenotype of ARDS – early  
51 improvement of ARDS, which occurred in about one third patients, and would predict a  
52 favorable clinical outcome.

## 53 **Methods**

### 54 Study design and participants

55 This retrospective cohort study included two cohorts of ICU patients from Chongqing public  
56 health medical center and Chongqing three gorges central hospital (Chongqing, China), both of  
57 which are designated hospital to treat patients with COVID-19 in Chongqing. Patients who  
58 admitted to ICU between Jan 21, 2020 (time of the first patient admitted) and March 15, 2020  
59 (time of the last patient discharged in the first wave), were enrolled in our study.

60 Patients with COVID-19 were confirmed by the positive real-time reverse transcriptase–  
61 polymerase chain reaction (RT-PCR) assay for nasal and pharyngeal swab specimens according  
62 to the WHO guidance. The severity of COVID-19 was judged according to the Fifth Revised  
63 Trial Version of the Novel Coronavirus Pneumonia Diagnosis and Treatment Guidance of  
64 China(10). Those who met the any following criteria were defined as severe-type: (1) respiratory

65 distress with a respiratory rate over 30 breaths per minute, (2) oxygen saturation  $\leq 93\%$  in the  
66 resting state, and (3) arterial blood oxygen partial pressure (PaO<sub>2</sub>) /oxygen concentration (FiO<sub>2</sub>)  
67  $\leq 300$  mm Hg. Those who met one of the following criteria were defined as critically ill-type: (1)  
68 mechanical ventilation needed for respiratory failure, (2) shock, and (3) intensive care needed  
69 owing to other organ failure.

70 The study was approved by the Research Ethics Commission of the second affiliated hospital of  
71 Chongqing medical university, Chongqing public health medical center and Chongqing three  
72 gorges central hospital. Written informed consent was waived by the Ethics Commission of the  
73 designated hospital for emerging infectious disease.

#### 74 Data collection

75 Both of the two designated hospitals are Grade A hospitals in China, and all the case data can be  
76 found in the electronic case system. Epidemiological, demographic, symptoms, underlying  
77 diseases, comorbidities, treatments, clinical course and outcome data of the patients were  
78 recorded in a spreadsheet. The signs, arterial blood gas analysis, laboratory data, acute  
79 physiology and chronic health evaluation II (APACHE II) and sequential organ failure  
80 assessment (SOFA) score were collected at the certain time (Day0: admission in hospital, Day1:  
81 admission in ICU, Day3, Day7 and Day14) for each patient. If there was no question about the  
82 case data, the doctor in charge was promptly inquired. As the data collection was completed,  
83 another doctor was responsible for checking and integrating. The proportion of pneumonia  
84 volume was calculated according to the pulmonary infection assisted diagnosis system (V1.7.0.1)  
85 based on the Computed Tomography image.

86 Definition

87 ARDS was diagnosed according to the Berlin Definition(11). Liver injury was diagnosed  
88 according to the following criteria: alanine aminotransferase (ALT) > 3 upperlimit of normal  
89 (ULN) or aspartate aminotransferase (AST) > 3ULN or Total bilirubin (TBIL) > 2ULN,  
90 regardless of chronic liver disease(12). Acute kidney injury was diagnosed on the basis of serum  
91 creatinine(13). Cardiac injury was diagnosed if the serum concentration of hypersensitive cardiac  
92 troponin T (hsTNT) was above the upper limit of the reference range (>14 pg/mL). Time of viral  
93 shedding was defined as when two consecutive SARS-CoV-2 PCR assays at least 24 h apart  
94 were negative.

95 Statistical analysis

96 SPSS26.0 (IBM SPSS Statistics, IBM Corporation) was used as the statistical analysis tool. The  
97 continuous variables that met the normal distribution are presented as mean  $\pm$  standard deviation,  
98 and the independent student's t test was used for comparison between two groups. The  
99 continuous variables that do not meet the normal distribution are presented as the median  
100 (interquartile ranges, IQR), and the Mann-Whitney U test was used between two groups.  
101 Categorical variables are summarized by using frequencies and percentages, and the  $\chi^2$  test or  
102 the Fisher exact test was used among two or more groups; We performed bivariate analyses to  
103 identify the predictors for early improvement of ARDS, variables with a P value < 0.05 in the  
104 univariate analysis were entered into multivariate logistic regression analysis. All tests were two-  
105 sided and  $p < 0.05$  were considered statistically significant.

106 **Result**

107 Clinical characteristics of ICU patients in Chongqing, China

108 From 21 January to 15 March 2020, Chongqing reported 576 new cases of COVID-19, with 6  
109 deaths. 75 ICU patients from two hospitals were included in this study, with 48 severe and 27  
110 critically ill patients, and 4 death.

111 The comparison of clinical characteristics between these two groups is shown in Table 1. The  
112 median age of the 75 patients was 57 years (IQR 25-75), and no bias in the sex ratio. Smoking  
113 was more prevalent in critically ill patients (30%) than the severe ones (2%,  $p = 0.002$ ). 16 (21%)  
114 patients had a history of exposure to Hubei province, 24 (32%) patients contacted with patients  
115 from Hubei, 17 (23%) patients contacted with confirmed patients in Chongqing, and 18 (24%)  
116 patients had no definite epidemiological link. The most frequent chronic medical illnesses were  
117 diabetes (27%) and hypertension (19%). The most common symptoms were cough (83%), fever  
118 (68%) and dyspnea (57%). 2 (3%) patients were under asymptomatic period before  
119 hospitalization, and appeared dyspnea without fever during the stay in hospital.

120 ARDS was developed in most of the patients (93%), and more than half were moderate (Table  
121 1). However, most of the patients (55%) supported with high flow nasal cannula (HFNC) oxygen  
122 therapy, 26 (35%) patients received non-invasive ventilation, and 7 (9%) patients received  
123 invasive ventilation. Other supportive treatments included: prone position ventilation in 7 (9%)  
124 patients, extracorporeal membrane oxygenation in 3 (4%), renal replacement therapy in 3 (4%),  
125 and vasoconstrictive agents in 7 (9%). Although bacterial pneumonia was identified by  
126 microbiological culture of sputum or alveolar lavage fluid in only 4 (5%) patients, the  
127 antibacterial agents were administered to 62 (83%) patients, and antifungal agents in 12 (16%)  
128 patients. Liver (25%) was the most commonly injured extrapulmonary organ, followed by  
129 cardiac (19%) and kidney (11%). Lymphopenia was a very noteworthy feature in these patients  
130 (95%), and lower incidence of leukopenia (25%) and thrombocytopenia (27%) relatively. Anti-

131 viral agents were used in all patients (100%), the combination of Aluvia (Lopinavir and  
132 Ritonavir Tablets) and interferon alpha was the most commonly used. Traditional Chinese  
133 medicine was used in 65 (87%) patients owing to potential anti-viral and anti-inflammation  
134 activity. Glucocorticoids was given to 46 (61%) patients, immunoglobulin to 30 (40%), and  
135 thymopeptides to 63 (84%).

#### 136 Clinical course and outcomes

137 The clinical course and outcomes of patients with COVID-19 in Chongqing are shown in Table  
138 2. Chongqing reported 6 deaths of COVID-19 up to 15 March 2020, with 1.04% mortality in all  
139 576 patients. Because 2 patients were died in the emergency department, only 4 dead patients  
140 with clinical data were included in our study, with 5.3% 28-Day case fatality rate and 1.3% 28-  
141 Day mechanical ventilation dependency in ICU patients. The duration from any initial symptoms  
142 to diagnose confirmed by PCR test was 5 days (IQR 2-7), to hospital admission 7 days (IQR 4-  
143 8), to ARDS 7 days (IQR 6-10), to ICU admission 8 days (IQR 6-11), to ventilation 10 days  
144 (IQR 7-14), to viral shedding 20 days (IQR 16-26), and to death 16 days (min 15, max 28). The  
145 length of ICU stay was 13 days (IQR 9-19) and hospital stay 22 days (IQR 16-34).

#### 146 Early improvement of ARDS

147 Learned from the clinical practice, we found a large group of ARDS patients would be improved  
148 in one week, we defined these patients as early improvement of ARDS (eiARDS). 56 patients  
149 who had ARDS ( $\text{PaO}_2/\text{FiO}_2 < 300\text{mmHg}$ ) on the first day of ICU admission (Day 1) were  
150 included for analysis. We defined two groups based on the severity of illness on Day 7 (Fig. 1A):  
151 “eiARDS” patients  $\text{PaO}_2/\text{FiO}_2 \geq 300\text{mmHg}$ , “Non-eiARDS” patients  $\text{PaO}_2/\text{FiO}_2 < 300\text{mmHg}$ .

152 18 patients got an eiARDS, accounted for nearly one third of the 56 ARDS patients. There are  
153 not significantly differences between the two groups in the PaO<sub>2</sub>/FiO<sub>2</sub> on Day 1 (Fig. 1B), the  
154 proportion of pneumonia volume on Day 1(Fig. 1C), and the rate of ventilator usage ( $z = 2.46$ ,  $p$   
155  $= 0.117$ ). Predictably and regrettably, all of the 4 dead patients did not get an early improvement  
156 of ARDS. What's more, patients of "eiARDS" stayed shorter in ICU than the "Non-eiARDS",  
157 with 10.5 days (IQR 8, 16) and 18 days (IQR 13, 22) respectively ( $p = 0.001$ ) (Fig. 1D).

158 In order to determine the factors associated with eiARDS, we performed a bivariate analysis. As  
159 shown in Table 3, 3 variables (Age, Temperature and hsCRP) with  $p < 0.05$  in the univariate  
160 analysis were chosen for multivariable analysis. Age ( $< 55$  years) was the only variable  
161 independently associated with eiARDS, with an odds ratio of 7.4 (95%CI: 1.80-31.08).  
162 Indicating that patients younger than 55 years old are 7.4 times more likely to get an early  
163 improvement of ARDS than older ones.

## 164 **Discussion**

165 In the present study, we found that the mortality of COVID-19 in Chongqing was 1.04%, and the  
166 28-Day case fatality rate of ICU patients was 5.3%. ARDS was developed in 93% ICU patients,  
167 and the HFNC was the most commonly used oxygen therapy. An early improvement of ARDS  
168 was occurred in about one third patients, and patients younger than 55 years old would be more  
169 likely to do this.

170 Mortality of COVID-19 varies widely in different periods and areas. In the early stage of  
171 outbreak, Wuhan reported 4.3% mortality in hospitalized patients(14), and 61.5% in critically ill  
172 patients(15). However, the mortality of ICU patients gradually decreased to 32.5-38.5% as time  
173 elapsed(16,17). This happened to be 26% in Lombardy Region, Italy(18) and 50% in Seattle



174 Region, America(19). In the present study, we found that only 5.3% case fatality rate of ICU  
175 patients was occurred in Chongqing. The big differences of the mortality probably due to  
176 whether the medical resources can be timely supplied, including health workers and hospital  
177 beds(20). As a matter of fact, a huge number of health workers from other provinces have been  
178 aided to Hubei province, with consecutively increased acute care beds(20). Similar to the model  
179 of Hubei, as the first cluster cases of COVID-19 was detected in Chongqing, 4 designated  
180 hospitals were arranged and prepared for patients with COVID-19 only, and also the medical  
181 experts from different hospitals in Chongqing. The centralized dispatcher of medical resources is  
182 the key experience of treating COVID-19 in China.

183 ARDS is the key factor to affect the mortality. According to the Berlin definition, stages of mild,  
184 moderate, and severe ARDS were associated with increased mortality (27%, 32% and 45%  
185 respectively)(11). Studies have shown that ARDS was one of the risk factors of death in patients  
186 with COVID-19(15,21). Many efforts have been attempted to treat ARDS. However, only  
187 mechanical ventilation was showed to be effective therapeutics(22). Interestingly, in our present  
188 study, although 93% patients had ever suffered ARDS, only 35% patients received non-invasive  
189 ventilation, and 9% patients received invasive ventilation. The most commonly used oxygen  
190 therapy was HFNC, which counted for 55% (despite patients may receive both HFNC and  
191 ventilation), seemly meaning that HFNC is effective for COVID-19-induced ARDS. Similar  
192 conclusions can be observed in a previous review(4). The authors hold that HFNC is suitable for  
193 COVID-19 patients with mild ARDS, and even safe for moderate and severe patients, which is  
194 clearly inconsistently with the stratified treatment strategies of ARDS caused by other factors(4).

195 In our present study, we found nearly one third patients with ARDS recovered in one week,  
196 which we defined as an early improvement of ARDS (eiARDS). However, this eiARDS can be

197 found in only 18% patients with mild ARDS caused by other factors, with 36% patients  
198 persisting and 46% worsened in the first week after ARDS onset(23). It is worth mentioning that,  
199 why so many patients with COVID-19 got an eiARDS and why HFNC oxygen therapy was so  
200 effectual for these patients? There is a voice should be considered. Gattinoni et al.(24) proposed  
201 two types of patients with COVID-19 pneumonia: “non-ARDS,” type 1, and ARDS, type 2.  
202 Although both types of patients meet the ARDS Berlin definition, but the severe hypoxemia in  
203 type 1 patients is associated with nearly normal respiratory system compliance, which can lead to  
204 ventilation/perfusion mismatch(24). Assuming that type 1 pneumonia would improve quicker  
205 than the type 2, it appears to be able to explain the above problems. In addition, Gattinoni et al  
206 proposed that the gas volume and percentage of non-aerated tissue can be clearly distinguished  
207 by CT scan between type 1 and type 2 pneumonia. However, there was not any differences in the  
208 proportion of pneumonia volume between “eiARDS” and “Non-eiARDS” in our study.

209 Regardless of the reasons why the proportion of eiARDS was so high, paying attention to  
210 eiARDS itself is clinically meaningful. Early or rapidly improving ARDS always associated with  
211 a better surviving or outcomes(23,25). For COVID-19 patients, early improvement in  
212 oxygenation was associated with being discharged alive from the ICU(21). We found that  
213 patients with eiARDS had a higher survival rate and lower length of ICU stay than the “Non-  
214 eiARDS”. Dynamic observation of ARDS in the short term is very worthwhile for the prognosis  
215 of COVID-19, and patients whose ARDS did not improve in one week should be given more  
216 attention.

217 One might point out that whether it is because most patients had mild ARDS at baseline, so it is  
218 easier to reach eiARDS. But the fact is that, in the baseline, 38.8% patients were under moderate  
219 ARDS, and no significantly differences were shown between “eiARDS” and “Non-eiARDS. In

220 other words, the initial PaO<sub>2</sub>/FiO<sub>2</sub> was independently associated with eiARDS. Indeed, multiple  
221 studies have shown that older age (> 65 years) is one of the risk factors of death in patients with  
222 COVID-19(15,26–28), and establishing risk stratification through age (> 60 years) maybe  
223 helpful to clinicians(29). Similar underlying mechanisms may be found in regard to the effect of  
224 age to death and the development of ARDS. Nevertheless, age should be given high attention  
225 during the management of COVID-19 patients.

### 226 **Limitations**

227 This study has several limitations. First, based on the retrospective study design, the laboratory  
228 tests (except arterial blood gas analysis, which performed each day) may not be performed in all  
229 patients at a specific time, and the missing data was replaced by the values within latest 2 days.  
230 Second, although the treatment strategies of the two hospitals followed the guidelines issued by  
231 the Chinese National Health Commission, some of the treatments are different, such as the  
232 composition of traditional Chinese medicine, which may cause different clinical outcomes.  
233 Third, the sample size is relatively small, part of the conclusions needs to be verified by multiple  
234 centers and larger sample size.

### 235 **Conclusions:**

236 In the present study, we described the epidemiology, clinical features, laboratory data,  
237 treatments, and outcomes of ICU patients in Chongqing, China. We found that the case fatality  
238 rate of ICU patients in this region was only 5.3%, and the timely supplement of medical  
239 resources and oxygen therapy based on HFNC may be the reasons for this low fatality rate. In  
240 addition, we identified a new subphenotype of ARDS – the early (in one week) improvement of  
241 ARDS (eiARDS), which occurred in about one third of ARDS patients with COVID-19,

242 anticipating a favorable clinical outcome. The age (< 55 years) is an independent predictor for  
243 the eiARDS, and stratification of COVID-19 patients by age is recommended.

#### 244 **Competing interests**

245 The authors declare that they have no competing interests.

#### 246 **Funding**

247 This work was supported by the Emergency Research Project of COVID-19 of Chongqing  
248 Health Commission (2020NCPZX04).

#### 249 **Acknowledgments**

250 We thank the patients described in this report, the health care personnel who cared for them, the  
251 staff members of Health Commission of Chongqing City, and the staff members of Chongqing  
252 Center for Disease Control and Prevention.

#### 253 **References**

- 254 1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from  
255 Patients with Pneumonia in China, 2019. *New England Journal of Medicine*. 2020 Jan  
256 24;0(0):null.
- 257 2. Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. *Acta Biomed*. 2020  
258 19;91(1):157–60.
- 259 3. World Health Organization. Coronavirus disease (COVID-19) Situation Report – 124.  
260 (2020). Accession at: [https://www.who.int/emergencies/diseases/novel-coronavirus-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports)  
261 2019/situation-reports

- 262 4. Li X, Ma X. Acute respiratory failure in COVID-19: is it “typical” ARDS? *Crit Care*.  
263 2020 06;24(1):198.
- 264 5. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of  
265 COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med*.  
266 2020;8(4):420–2.
- 267 6. Nunes Duarte-Neto A, de Almeida Monteiro RA, da Silva LFF, Malheiros DMAC, de  
268 Oliveira EP, Theodoro Filho J, et al. Pulmonary and systemic involvement of COVID-19  
269 assessed by ultrasound-guided minimally invasive autopsy. *Histopathology*. 2020 May 22;
- 270 7. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al.  
271 Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. *N Engl J*  
272 *Med*. 2020 May 21;
- 273 8. Tang X, Du R, Wang R, Cao T, Guan L, Yang C, et al. Comparison of Hospitalized  
274 Patients With ARDS Caused by COVID-19 and H1N1. *Chest*. 2020 Mar 26;
- 275 9. Liu Y, Sun W, Li J, Chen L, Wang Y, Zhang L, et al. Clinical features and progression of  
276 acute respiratory distress syndrome in coronavirus disease 2019. *medRxiv*. 2020 Feb  
277 21;2020.02.17.20024166.
- 278 10. National Health Commission of the Peoples Republic of China. The Fifth Revised Trial  
279 Version of the Novel Coronavirus Pneumonia Diagnosis and Treatment Guidance. Available  
280 at:  
281 <http://www.nhc.gov.cn/ztyqj/s7653p/202002/d4b895337e19445f8d728fcaf1e3e13a.shtml>.
- 282 11. ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson  
283 ND, Caldwell E, et al. Acute respiratory distress syndrome: the Berlin Definition. *JAMA*.  
284 2012 Jun 20;307(23):2526–33.

- 285 12. Chinese Digestion Association, Chinese Medical Doctor Association, Chinese Society of  
286 Hepatology, Chinese Medical Association. [The protocol for prevention, diagnosis and  
287 treatment of liver injury in coronavirus disease 2019]. Chinese Journal of Hepatology. 2020  
288 Mar 20;28(3):217–21.
- 289 13. KDIGO clinical practice guideline for acute kidney injury. Kidney disease: improving  
290 global outcomes (KDIGO) acute kidney injury work group. 2012 Mar; Available from:  
291 <https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf>
- 292 14. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138  
293 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China.  
294 JAMA [Internet]. 2020 Feb 7 [cited 2020 Feb 8]; Available from:  
295 <https://jamanetwork.com/journals/jama/fullarticle/2761044>
- 296 15. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of  
297 critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered,  
298 retrospective, observational study. Lancet Respir Med. 2020 Feb 24;
- 299 16. Yu Y, Xu D, Fu S, Zhang J, Yang X, Xu L, et al. Patients with COVID-19 in 19 ICUs in  
300 Wuhan, China: a cross-sectional study. Crit Care. 2020 14;24(1):219.
- 301 17. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality  
302 in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020 Apr 12;
- 303 18. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline  
304 Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to  
305 ICUs of the Lombardy Region, Italy. JAMA. 2020 Apr 6;
- 306 19. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Covid-19  
307 in Critically Ill Patients in the Seattle Region - Case Series. N Engl J Med. 2020 Mar 30;

- 308 20. Zhang Z, Yao W, Wang Y, Long C, Fu X. Wuhan and Hubei COVID-19 mortality  
309 analysis reveals the critical role of timely supply of medical resources. *J Infect.* 2020 Mar 21;
- 310 21. Zangrillo A, Beretta L, Scandroglio AM, Monti G, Fominskiy E, Colombo S, et al.  
311 Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with  
312 COVID-19 ARDS in Milan, Italy. *Crit Care Resusc.* 2020 Apr 23;
- 313 22. Fan E, Brodie D, Slutsky AS. Acute Respiratory Distress Syndrome: Advances in  
314 Diagnosis and Treatment. *JAMA.* 2018 20;319(7):698–710.
- 315 23. Pham T, Serpa Neto A, Pelosi P, Laffey JG, De Haro C, Lorente JA, et al. Outcomes of  
316 Patients Presenting with Mild Acute Respiratory Distress Syndrome: Insights from the  
317 LUNG SAFE Study. *Anesthesiology.* 2019;130(2):263–83.
- 318 24. Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia: ARDS or not? *Crit Care*  
319 [Internet]. 2020 Apr 16 [cited 2020 May 10];24. Available from:  
320 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160817/>
- 321 25. Schenck EJ, Oromendia C, Torres LK, Berlin DA, Choi AMK, Siempos II. Rapidly  
322 Improving ARDS in Therapeutic Randomized Controlled Trials. *Chest.* 2019;155(3):474–82.
- 323 26. Du R-H, Liang L-R, Yang C-Q, Wang W, Cao T-Z, Li M, et al. Predictors of Mortality  
324 for Patients with COVID-19 Pneumonia Caused by SARS-CoV-2: A Prospective Cohort  
325 Study. *Eur Respir J.* 2020 Apr 8;
- 326 27. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute  
327 Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019  
328 Pneumonia in Wuhan, China. *JAMA internal medicine* [Internet]. 2020; Available from:  
329 <http://www.ncbi.nlm.nih.gov/pubmed/32167524>

330 28. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for  
 331 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.  
 332 The Lancet. 2020 Mar;S0140673620305663.

333 29. Liu Y, Mao B, Liang S, Yang J, Lu H, Chai Y, et al. Association between ages and  
 334 clinical characteristics and outcomes of coronavirus disease 2019. European Respiratory  
 335 Journal [Internet]. 2020 Jan 1 [cited 2020 May 11]; Available from:  
 336 <https://erj.ersjournals.com/content/early/2020/04/20/13993003.01112-2020>

337  
 338 **Table 1.** Clinical characteristics of ICU patients (severe/critically ill) with COVID-19.

	Total (n=75)	Severe (n=48)	Critically ill (n=27)*	<i>p</i> value
Age, median (IQR), y	57 (25, 75)	56 (47, 70)	63 (51, 69)	0.566
Sex				0.644
Female	36 (48%)	24 (50%)	12 (44%)	..
Male	39 (52%)	24 (50%)	15 (56%)	..
Smoking	9 (12%)	1 (2%)	8 (30%)	0.002
<b>Exposure</b>				0.052
a recent travel to Hubei province	16 (21%)	13 (27%)	3 (11%)	..
contact with patients from Hubei	24 (32%)	18 (38%)	6 (22%)	..
contact with confirmed patients	17 (23%)	7 (15%)	10 (37%)	..
No definite epidemiological link	18 (24%)	10 (21%)	8 (30%)	..
<b>Chronic medical illness</b>				
Hypertension	14 (19%)	8 (17%)	6 (22%)	0.553
Diabetes	20 (27%)	12 (25%)	8 (30%)	0.663



Chronic cardiac disease	7 (9%)	6 (13%)	1 (4%)	0.399
COPD	4 (5%)	4 (8%)	0 (0%)	0.314
Malignancy	1 (1%)	1 (2%)	0 (0%)	1
<b>Symptoms</b>				
Fever	51 (68%)	28 (58%)	23 (85%)	0.017
Cough	62 (83%)	40 (83%)	22 (81%)	1
Expectoration	29 (39%)	21 (44%)	8 (30%)	0.228
Dyspnea	43 (57%)	23 (48%)	20 (74%)	0.028
Myalgia	20 (27%)	12 (25%)	8 (30%)	0.663
Headache	9 (12%)	7 (15%)	2 (7%)	0.584
Diarrhea	7 (9%)	4 (8%)	3 (11%)	1
<b>Comorbidities</b>				
ARDS†	70 (93%)	43 (90%)	27 (100%)	0.012
Without	5 (7%)	5 (10%)	0 (0%)	..
Mild	10 (13%)	9 (19%)	1 (4%)	..
Moderate	38 (51%)	25 (52%)	13 (48%)	..
Severe	22 (29%)	9 (19%)	13 (48%)	..
Pneumothorax	1 (1%)	0 (0%)	1 (4%)	0.769
Bacterial pneumonia‡	4 (5%)	3 (6%)	1 (4%)	1
Cardiac injury	14 (19%)	7 (15%)	7 (26%)	0.226
Liver injury	19 (25%)	10 (21%)	9 (33%)	0.232
Kidney injury	8 (11%)	5 (10%)	3 (11%)	1
Shock	7 (9%)	0 (0%)	7 (26%)	0.001
Leukopenia	19 (25%)	11 (23%)	8 (30%)	0.521
Lymphopenia	71 (95%)	46 (96%)	25 (93%)	0.949

Thrombocytopenia	20 (27%)	9 (19%)	11 (41%)	0.039
<b>Treatment</b>				
High flow nasal cannula	41 (55%)	20 (42%)	21 (78%)	0.003
Mechanical ventilation				
Non-invasive	26 (35%)	0 (0%)	26 (96%)	<0.0001
Invasive	7 (9%)	0 (0%)	7 (26%)	0.001
Prone position ventilation	7 (9%)	0 (0%)	7 (26%)	0.001
Extracorporeal membrane oxygenation	3 (4%)	0 (0%)	3 (11%)	0.081
Renal replacement therapy	3 (4%)	0 (0%)	3 (11%)	0.081
Vasoconstrictive agents	7 (9%)	0 (0%)	7 (26%)	0.001
Antiviral agents	75 (100%)	48 (100%)	27 (100%)	NA
Antibacterial agents	62 (83%)	37 (77%)	25 (93%)	0.166
Antifungal	12 (16%)	4 (8%)	8 (30%)	0.037
Glucocorticoids	46 (61%)	22 (46%)	24 (89%)	0.0002
Immunoglobulin	30 (40%)	13 (27%)	17 (63%)	0.002
Thymopeptides	63 (84%)	37 (77%)	26 (96%)	0.064
Traditional Chinese medicine	65 (87%)	41 (85%)	24 (89%)	0.944

339 Abbreviations: IQR, interquartile range; COPD, chronic obstructive pulmonary disease; ARDS,  
340 acute respiratory distress syndrome.

341 \*4 patients died in ICU were included.

342 †ARDS stages were defined by the worst PaO<sub>2</sub>/FiO<sub>2</sub>.

343 ‡Bacterial pneumonia was confirmed by sputum or alveolar lavage fluid culture.

344

**Table 2.** Clinical course and outcomes of ICU patients with COVID-19.

---

Duration from any initial symptoms*	Median (IQR), days
to diagnose confirmed by PCR test	5 (2, 7)
to hospital admission	7 (4, 8)
to ARDS	7 (6, 10)
to ICU admission	8 (6, 11)
to ventilation	10 (7, 14)
to viral shedding†	20 (16, 26)
to death‡	16 (min 15, max 28)
Length of ICU stay	13 (9, 19)
Length of hospital stay	22 (16, 34)

---

Outcomes (n = 75)	NO. (%)
28-Day Mortality‡	4 (5.3)
28-Day mechanical ventilation dependency	1 (1.3)
Location of death (n = 6)	
ICU	4 (66.7)
Emergency department	2 (33.3)

---

345 Abbreviations: PCR, polymerase chain reaction; ICU, intensive care unit; IQR, interquartile  
346 range.

347 \*2 patients without any symptoms until hospital admission were excluded for statistical analysis.

348 †The viral shedding was defined as two or more consecutive throat swab PCR test were negative.

349 ‡4 patients died in ICU were included.

350

351

352

353 **Table 3.** Univariate and multivariate analysis of predictors for early improvement of ARDS.

	Variable OR (95% CI)	p value
<b>Demographics and clinical characteristics</b>		
Age, years*		
>=55	1 (ref)	
<55 (univariate)	4.33 (1.31-14.32)	0.016
<55 (multivariate)	7.40 (1.80-31.08)	0.006
Male sex (vs female)	2.00 (0.62-6.43)	0.245
Time of onset to ICU	1.03 (0.87-1.22)	0.704
Smoke	2.43 (0.53-11.10)	0.252
Hypertension	0.55 (0.10-2.98)	0.491
Diabetes	0.80 (0.21-3.01)	0.741
COPD	0.69 (0.07-7.10)	0.752
APACHE II	0.85 (0.70-1.05)	0.130
SOFA	0.96 (0.56-1.67)	0.889
Temperature, °C*		
<37.3	1 (ref)	
>=37.3 (univariate)	0.22 (0.06-0.90)	0.034
>=37.3 (multivariate)	0.307 (0.06-1.68)	0.173
Heart rate, /min		
<100	1 (ref)	
>=100	2.54 (0.63-10.25)	0.191
Respiratory rate, /min		

<24	1 (ref)	
>=24	1.27 (0.32-5.04)	0.738
<b>Systolic pressure, mmHg</b>		
<140	1 (ref)	
>=140	1.21 (0.47-3.10)	0.695
Ventilation (vs Non-)	0.83 (0.14-4.73)	0.829
Proportion of pneumonia volume, %	0.97 (0.92-1.02)	0.227
<b>Laboratory findings</b>		
<b>pH</b>		
7.35-7.45	1 (ref)	
>7.45	1.68 (0.46-6.21)	0.437
<b>PaCO<sub>2</sub>, mmHg</b>		
34-45	1 (ref)	
<34	1.10 (0.35-3.46)	0.873
<b>PaO<sub>2</sub>, mmHg</b>		
>=60	1 (ref)	
<60	0.44 (0.12-1.59)	0.209
<b>White blood cell count, × 10<sup>3</sup>/L</b>		
<4	3.63 (0.97-13.64)	0.056
4-10	1 (ref)	
>10	2.07 (0.30-14.44)	0.461
Lymphocyte, ×10 <sup>3</sup>	2.73 (0.54-13.80)	0.224
<b>Platelet, × 10<sup>3</sup>/L</b>		
>=100	1 (ref)	
<100	2.19 (0.28-16.95)	0.454

---

Potassium, mmol/L		
3.5-4.5	1 (ref)	
<3.5	0.51 (0.12-2.12)	0.352
Sodium, mmol/L		
135-145	1 (ref)	
<135	1.05 (0.34-3.27)	0.933
Creatinine, $\mu\text{mol/L}$	1.00 (0.97-1.03)	0.804
Albumin, g/L		
$\geq 40$	1 (ref)	
<40	0.57 (0.11-2.87)	0.491
Total bilirubin, $\mu\text{mol/L}$		
$\leq 17.1$	1 (ref)	
>17.1	1.96 (0.61-6.29)	0.256
Alanine aminotransferase, U/L		
$\leq 40$	1 (ref)	
>40	0.59 (0.17-2.00)	0.396
Creatine kinase, U/L		
$\leq 200$	1 (ref)	
>200	0.72 (0.17-3.10)	0.657
High-sensitivity cardiac troponin T, ng/mL, ng/mL		
$\leq 0.014$	1 (ref)	
>0.014	0.70 (0.06-7.74)	0.774
Prothrombin time, sec		
$\leq 14$	1 (ref)	
>14	2.53 (1.23-5.19)	0.999

---

---

D-dimer, µg/L		
<=0.55	1 (ref)	
>0.55	0.94 (0.27-3.26)	0.928
Procalcitonin, ng/ml		
<=0.046	1 (ref)	
>0.046	0.32 (0.09-1.17)	0.084
hsCRP, mg/L* (univariate)	0.99 (0.98-1.00)	0.041
hsCRP, mg/L (multivariate)	0.99 (0.98-1.00)	0.092

---

354 Abbreviations: OR, odds ratio; ICU, intensive care unit; COPD, chronic obstructive pulmonary  
355 disease; APACHE, acute physiology and chronic health evaluation; SOFA, sequential organ  
356 failure assessment; PaCO<sub>2</sub>, arterial partial pressure of carbon dioxide; PaO<sub>2</sub>, arterial partial  
357 pressure of oxygen; hsCRP, high-sensitivity C reaction protein.


358 \* 3 variables (Age, Temperature and hsCRP) were chosen for multivariable analysis.

359


360 **Figure 1. Legend.**

361 Comparison between “eiARDS” and “Non-eiARDS”. (A) All patients were under ARDS on Day  
362 1, but divided into two groups (eiARDS and Non-eiARDS) according to the PaO<sub>2</sub>/FiO<sub>2</sub> on Day  
363 7. (B) No significantly difference between two groups in the PaO<sub>2</sub>/FiO<sub>2</sub> on Day 1. (C) No  
364 significantly difference between two groups in the proportion of pneumonia volume on Day 1.  
365 (D) The length of ICU stay showed different between two groups. eiARDS, early improvement  
366 of ARDS; Non-eiARDS, none of eiARDS.


A



B



C



D

